2020 Virtual ESMO Review


 

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine Amivantamab + Lazertinib in Advanced EGFR+ Disease?

29 views
November 25, 2020
Comments 0
Login to view comments. Click here to Login